全文获取类型
收费全文 | 2996篇 |
免费 | 280篇 |
国内免费 | 33篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 162篇 |
妇产科学 | 94篇 |
基础医学 | 338篇 |
口腔科学 | 115篇 |
临床医学 | 313篇 |
内科学 | 481篇 |
皮肤病学 | 92篇 |
神经病学 | 117篇 |
特种医学 | 303篇 |
外科学 | 410篇 |
综合类 | 100篇 |
预防医学 | 220篇 |
眼科学 | 52篇 |
药学 | 200篇 |
中国医学 | 2篇 |
肿瘤学 | 279篇 |
出版年
2023年 | 23篇 |
2022年 | 28篇 |
2021年 | 42篇 |
2020年 | 35篇 |
2019年 | 33篇 |
2018年 | 76篇 |
2017年 | 67篇 |
2016年 | 74篇 |
2015年 | 91篇 |
2014年 | 121篇 |
2013年 | 170篇 |
2012年 | 144篇 |
2011年 | 122篇 |
2010年 | 135篇 |
2009年 | 137篇 |
2008年 | 105篇 |
2007年 | 126篇 |
2006年 | 134篇 |
2005年 | 85篇 |
2004年 | 89篇 |
2003年 | 70篇 |
2002年 | 79篇 |
2001年 | 61篇 |
2000年 | 65篇 |
1999年 | 68篇 |
1998年 | 128篇 |
1997年 | 97篇 |
1996年 | 116篇 |
1995年 | 74篇 |
1994年 | 86篇 |
1993年 | 48篇 |
1992年 | 39篇 |
1991年 | 40篇 |
1990年 | 37篇 |
1989年 | 54篇 |
1988年 | 44篇 |
1987年 | 49篇 |
1986年 | 56篇 |
1985年 | 42篇 |
1984年 | 21篇 |
1983年 | 15篇 |
1982年 | 25篇 |
1981年 | 18篇 |
1980年 | 18篇 |
1979年 | 12篇 |
1978年 | 9篇 |
1977年 | 13篇 |
1976年 | 17篇 |
1975年 | 15篇 |
1973年 | 11篇 |
排序方式: 共有3309条查询结果,搜索用时 484 毫秒
111.
Hematopoietic growth factors (HGFs) interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) individually have been shown to increase the percentage of acute myeloid leukemia (AML) blasts in S phase and enhance the cytotoxic effects of Ara-C against these blasts in culture. We compared in vitro the effects of a combined treatment with GM-CSF (10 ng/mL) plus IL-3 (10 ng/mL) on the metabolism and cytotoxicity of Ara-C in normal bone marrow mononuclear cells (NBMMC) and AML blasts. NBMMC from six healthy volunteers and AML blasts from 10 patients were incubated for 20 hours with or without IL- 3 plus GM-CSF, followed by a concurrent treatment with Ara-C for 4 additional hours. Exposure to the HGFs and Ara-C produced significantly higher intracellular Ara-CTP levels as well as higher Ara-CTP/dCTP pool ratios in AML blasts as compared with NBMMC. Treatment with HGFs resulted in [3H] Ara-C DNA incorporation that was significantly higher in AML blasts versus NBMMC. This selective improvement of Ara-C metabolism in AML blasts was associated with an enhanced Ara-C-mediated leukemia colony-forming unit (CFU) growth inhibition. In contrast, exposure to HGFs resulted in an improved colony growth of normal CFU granulocyte-monocyte and CFU-granulocyte, erythroid, monocyte, megakaryocyte. These in vitro studies indicate that a combined treatment with IL-3 plus GM-CSF may improve the selectivity of Ara-C against AML blasts. 相似文献
112.
Aniket Bankar Thirushi Piyumika Siriwardena Biljana Rizoska Christina Rydergrd Helen Kylefjord Vilma Rraklli Anders Eneroth Pedro Pinho Stefan Norin Johan Bylund Sara Moses Richard Bethell Simon Kavanagh Neil Maclean Marcela Gronda Xiaoming Wang Rose Hurren Mark D. Minden Paul Targett-Adams Aaron D. Schimmer Mark Albertella 《Haematologica》2021,106(2):574
113.
114.
115.
Simon D. Brandt Pierce V. Kavanagh Folker Westphal Alexander Stratford Simon P. Elliott Geraldine Dowling Adam L. Halberstadt 《Drug testing and analysis》2020,12(10):1514-1521
Recent investigations have shown that N‐ethyl‐N‐cyclopropyl lysergamide (ECPLA) produces LSD‐like behavioral effects in mice, which suggests that it may act as a hallucinogen in humans. Although the use of ECPLA as a recreational drug has been limited, key analytical data that can be used to detect ECPLA are required for future forensic and clinical investigations. ECPLA is an isomer of (2′S,4′S)‐lysergic acid 2,4‐dimethylazetidide (LSZ), a lysergamide that emerged as a recreational drug in 2013. Several analytical approaches were examined, including single‐ and tandem mass spectrometry platforms at low and high resolution, gas‐ and liquid chromatography (GC, LC), nuclear magnetic resonance spectroscopy (NMR), and GC condensed‐phase infrared spectroscopy (GC‐sIR). ECPLA and LSZ could be differentiated by NMR, GC‐sIR, GC, and LC‐based methods. The electron ionization mass spectra of ECPLA and LSZ contained ion clusters typically observed with related lysergamides such as m/z 150–155, m/z 177–182, m/z 191–197, m/z 205–208, and m/z 219–224. One of the significant differences in abundance related to these clusters included ions at m/z 196 and m/z 207/208. The base peaks were detected at m/z 221 in both cases followed by the retro‐Diels‐Alder fragment at m/z 292. Minor but noticeable differences between the two isomers could also be seen in the relative abundance of m/z 98 and m/z 41. Electrospray ionization mass spectra included lysergamide‐related ions at m/z 281, 251, 223, 208, 197, 180, and 140. LSZ (but not ECPLA) showed product ions at m/z 267 and m/z 98 under the conditions used. 相似文献
116.
Simon D. Brandt Pierce V. Kavanagh Folker Westphal Alexander Stratford Anna U. Odland Adam K. Klein Geraldine Dowling Nicola M. Dempster Jason Wallach Torsten Passie Adam L. Halberstadt 《Drug testing and analysis》2020,12(6):812-826
Lysergic acid diethylamide (LSD) is a prototypical serotonergic psychedelic drug and the subject of many clinical investigations. In recent years, a range of lysergamides has emerged with the production of some being inspired by the existing scientific literature. Others, for example various 1‐acyl substituted lysergamides, did not exist before their appearance as research chemicals. 1‐Cylopropanoyl‐LSD (1CP‐LSD) has recently emerged as a new addition to the group of lysergamide‐based designer drugs and is believed to be psychoactive in humans. In this investigation, 1CP‐LSD was subjected to detailed analytical characterizations including various mass spectrometry (MS) platforms, gas and liquid chromatography, nuclear magnetic resonance spectroscopy, solid phase and GC condensed phase infrared spectroscopy. Analysis by GC–MS also revealed the detection of artificially induced degradation products. Incubation of 1CP‐LSD with human serum led to the formation of LSD, indicating that it may act as a prodrug for LSD in vivo, similar to other 1‐acyl substituted lysergamides. The analysis of blotters and pellets is also included. 1CP‐LSD also induces the head‐twitch response (HTR) in C57BL/6 J mice, indicating that it produces an LSD‐like behavioural profile. 1CP‐LSD induced the HTR with an ED50 = 430.0 nmol/kg which was comparable to 1P‐LSD (ED50 = 349.6 nmol/kg) investigated previously. Clinical studies are required to determine the potency and profile of the effects produced by 1CP‐LSD in humans. 相似文献
117.
118.
119.
120.
E Rees G Kirov J T Walters A L Richards D Howrigan D H Kavanagh A J Pocklington M Fromer D M Ruderfer L Georgieva N Carrera P Gormley P Palta H Williams S Dwyer J S Johnson P Roussos D D Barker E Banks V Milanova S A Rose K Chambert M Mahajan E M Scolnick J L Moran M T Tsuang S J Glatt W J Chen H-G Hwu The Taiwanese Trios Exome Sequencing Consortium B M Neale A Palotie P Sklar S M Purcell S A McCarroll P Holmans M J Owen M C O'Donovan 《Translational psychiatry》2015,5(7):e607
Genetic associations involving both rare and common alleles have been reported for schizophrenia but there have been no systematic scans for rare recessive genotypes using fully phased trio data. Here, we use exome sequencing in 604 schizophrenia proband–parent trios to investigate the role of recessive (homozygous or compound heterozygous) nonsynonymous genotypes in the disorder. The burden of recessive genotypes was not significantly increased in probands at either a genome-wide level or in any individual gene after adjustment for multiple testing. At a system level, probands had an excess of nonsynonymous compound heterozygous genotypes (minor allele frequency, MAF ⩽1%) in voltage-gated sodium channels (VGSCs; eight in probands and none in parents, P=1.5 × 10−4). Previous findings of multiple de novo loss-of-function mutations in this gene family, particularly SCN2A, in autism and intellectual disability provide biological and genetic plausibility for this finding. Pointing further to the involvement of VGSCs in schizophrenia, we found that these genes were enriched for nonsynonymous mutations (MAF ⩽0.1%) in cases genotyped using an exome array, (5585 schizophrenia cases and 8103 controls), and that in the trios data, synaptic proteins interacting with VGSCs were also enriched for both compound heterozygosity (P=0.018) and de novo mutations (P=0.04). However, we were unable to replicate the specific association with compound heterozygosity at VGSCs in an independent sample of Taiwanese schizophrenia trios (N=614). We conclude that recessive genotypes do not appear to make a substantial contribution to schizophrenia at a genome-wide level. Although multiple lines of evidence, including several from this study, suggest that rare mutations in VGSCs contribute to the disorder, in the absence of replication of the original findings regarding compound heterozygosity, this conclusion requires evaluation in a larger sample of trios. 相似文献